Delcath Systems, Inc. (DCTH)

0.10
OTC Markets
Prev Close 0.11
Day Low/High 0.09 / 0.11
52 Wk Low/High 0.06 / 10.30
Exchange OTC Markets
Shares Outstanding 18.28B
Market Cap 2.01M
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: YM Bio, Infinity, Delcath and Galena

Biotech Stock Mailbag: YM Bio, Infinity, Delcath and Galena

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

AP Pharma, Delcath Systems: FDA 'Acceptance' Run-Up Trades

AP Pharma, Delcath Systems: FDA 'Acceptance' Run-Up Trades

The biotech bull market has created a new category of swing trade catalysts.

3 Health Care Stocks Under $10 Making Big Moves

3 Health Care Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine

Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Delcath Systems 's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Delcath Systems 's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Delcath Systems 's CEO Discusses Q2 2012 Results - Earnings Call Transcript

BIO CEO Confab Live Blog Replay: Day 2

BIO CEO Confab Live Blog Replay: Day 2

Follow all the news and social media commentary from the BIO CEO & Investor Conference

Catching the Wave: Parabolas Abound

Catching the Wave: Parabolas Abound

And the winner of the Granddaddy Parabolic Pattern Award is …

Biotech Stock Mailbag: Mela Sciences

Biotech Stock Mailbag: Mela Sciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Catching the Wave: When the Bough Breaks

Catching the Wave: When the Bough Breaks

Though a gold decline below $1,000 per ounce seems hard to imagine, Elliott Wave and Fibonacci theories have made similarly outrageous predictions in the past that were ultimately fulfilled.

Biotech Calendar: Key Dates for September

Biotech Calendar: Key Dates for September

Here's a list of September's potentially stock-moving biotech events.

Biotech Stock Mailbag: Celsion

Biotech Stock Mailbag: Celsion

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

'Mad Money Lightning Round': Go for Exelixis

'Mad Money Lightning Round': Go for Exelixis

Cramer says Exelixis is a darn good spec stock.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Sweet Spot in Biotech Investing

Sweet Spot in Biotech Investing

Phase II trials of a drug can be a profitable undertaking for investors.

Delcath: Safety Questions Behind FDA Delay

Delcath: Safety Questions Behind FDA Delay

Delcath CEO says FDA issued a refuse-to-file letter because regulators want more safety data on the chemo drug used in Delcath's liver tumor-clearance system.

Delcath Hit With FDA Approval Delay

Delcath Hit With FDA Approval Delay

FDA refuses to accept approval application for Delcath's live tumor clearance device.

'Mad Money Lightning Round': Tiffany Sparkles

'Mad Money Lightning Round': Tiffany Sparkles

Cramer says the stock can go substantially higher.

10 Health Care Stocks With 100% Buy Ratings

10 Health Care Stocks With 100% Buy Ratings

Analysts have 100% buy recommendations on these stocks, based on growing global demand for medical devices and services.

Biotech Stock Mailbag: Clinical Data, Mannkind and Thanks!

Biotech Stock Mailbag: Clinical Data, Mannkind and Thanks!

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Biotech Calendar: FDA Drug Approvals in 2011

Biotech Calendar: FDA Drug Approvals in 2011

A list of drug and biotech firms with drug approvals expected in 2011.

Biotech Calendar: Key Dates for December

Biotech Calendar: Key Dates for December

Here's a list of December's potentially stock-moving biotech events.

Biotech Stock Mailbag: Aastrom BioSciences

Biotech Stock Mailbag: Aastrom BioSciences

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010

Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010

The Encompass Fund (ENCPX), www.encompassfund.

Biotech Stock Mailbag: Exact Sciences

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag: Avanir Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Pacific Ethanol, Mannkind: Volume Movers

Several stocks trading near $5, including Pacific Ethanol, were poised to move on above-average volume Tuesday.

Pep Boys CEO, Mining Stocks, Recession Beaters

Pep Boys CEO, Mining Stocks, Recession Beaters

Gregg Greenberg breaks down today's market action with guests Mike Odell, CEO of The Pep Boys, Malcolm Gissen, portfolio manager for the Encompass fund and Frank Ingarra, portfolio manager for the Hennessy Focus 30 fund.

Biotech Stock Mailbag Readers' Portfolio: Update

The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 11% this year.

Biotech Stock Mailbag: ASCO

Adam Feuerstein answers readers' questions about health care- and drug-related companies.